CompletedNCT02508493Updated Oct 27, 2021

Validation of the THINC-it Tool for Cognitive Dysfunction in Major Depressive Disorder

An observational study in Major Depressive Disorder, sponsored by Brain and Cognition Discovery Foundation. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-27.

Sponsored by Brain and Cognition Discovery Foundation · Observational

Study type: Observational
Model: Case-control
Time perspective: Cross-sectional
Enrollment: 200
Ages: 18 Years to 65 Years
Sex: All

Study summary

Cognitive dysfunction is a highly persistent, pervasive and progressive abnormality in young adults (i.e., 18-65 years) with MDD. It has also been shown that among adults with MDD who are gainfully employed, measures of cognition are a greater determinant of overall workplace performance than is total depression symptom severity. Several lines of evidence indicate that cognitive deficits that persist between episodes of depression are critical determinants of functional recovery in the workplace. The functional implications associated with cognitive impairment provide the impetus for systematic evaluation, measurement and assessment of the domains of cognition expected to be impaired in this patient population.

To date, no measurement tool has been sufficiently validated and/or determined to be sensitive to the cognitive deficits in younger adults with MDD. Major limitations of available comprehensive psychometric tools include relative lack of availability, cost, lack of access to most healthcare providers, and above all else, the lengthy time to administer. Moreover, the need for a psychometrist to interpret the results adds to the complexity and the costliness of such an endeavor.

It is imperative that any tool recommended for clinical utility be aligned with the busy nature of a high-volume clinical practice. The ideal gold standard tool for assessing the presence of cognitive dysfunction in MDD in the clinical environment should include, but not be limited to, features such as good conceptual coverage of cognitive domains affected in MDD, good sensitivity and reliability, and it should be relatively uninfluenced by culture effects and practice effects. The tool would also need to be brief, easy to administer and interpret, and complement busy clinical practice.

This study is designed to validate a brief user-friendly tool capable of detecting deficit in cognitive performance among adults with MDD. Data will be gathered with the aim to determine whether the proposed tool identifies cognitive deficits in adults with MDD and differentiates the clinical MDD population from healthy controls.

It is anticipated that the THINC-it tool will be free of charge and downloadable from the THINC-it website for use in the primary care and specialty setting. The THINC-it tool will be accessible via computers/tablets, will take 20 minutes to self-administer in a clinical setting, and the performance results will be immediately available.

Conditions studied

Major Depressive Disorder

Browse trials for

In context

Depressive Disorder

4,845 studies on the registry are indexed under Depressive Disorder; 514 are open to participants now.

This study's planned enrollment of 200 is above the median of 150 across 653 observational studies indexed under Depressive Disorder.

Browse Depressive Disorder studies →

Lead sponsor

Brain and Cognition Discovery Foundation is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 65 Years
Sexes eligible: All
Accepts healthy volunteers: Yes
Sampling method: Non-probability sample

Study population

All patients will be enrolled at a single site, located in Toronto, Ontario, Canada. The total planned number of participants is:

100 individuals with DSM-5-defined MDD, aged 18-65
100 healthy controls matched on age, sex and years of education An equal allocation of subjects with MDD between the ages of 18-44 and 45-65 will be enrolled.

Healthy controls will be consecutively recruited via media announcements.

Eligibility criteria

MDD Population:

Inclusion Criteria:

That participant is able and willing to provide informed consent.
The participant is male or female between the ages of 18-65.
The participant has received a diagnosis of a major depressive disorder (MDE) as per DSM-5 criteria.
Current MDE is confirmed by the MINI for DSM-IV-TR.
The participant is an outpatient at a psychiatric setting.
The participant has a MADRS score equal to or greater than 22.
The reported duration of current depressive episode is at least 3 months.
The participant has been receiving a stable antidepressant dose for a minimum of 2 weeks prior to the study visit.
At least one prior episode by history of depression validated by previous treatment (e.g. guidelines-informed pharmacotherapy and/or manual-based psychotherapy).
Health Canada-approved antidepressant; add-on agents commensurate with Canadian (i.e. CANMAT) and American treatment-guidelines for MDD will be permitted.
Enrollment in manual-based and/or supportive psychotherapy will be permitted.

Exclusion Criteria:

Current alcohol and/or substance use disorder.
Presence of comorbid psychiatric disorder other than MDD that is a focus of clinical concern as confirmed by the MINI for DSM-IV-TR.
Medications approved for and/or employed off label for cognitive dysfunction (e.g. psychostimulants).
Any medication for a general medical disorder that in the opinion of the investigator may affect cognitive function (e.g. corticosteroids, beta-blockers).
Use of benzodiazepines within 12 hours of THINC-it tool administration.
Consumption of alcohol within 8 hours of THINC-it tool administration.
The patient has physical, cognitive, or language impairment of some severity as to adversely affect the validity of the data derived from neuropsychological tests.
The patient is diagnosed with a reading disability or dyslexia.
The patient cannot have a clinically significant learning disorder by history.
The patient has received electroconvulsive therapy (ECT) in the last 6 months.
The patient has a history of moderate or severe head trauma (e.g. loss of consciousness for over 1 hour), other neurological disorders, or unstable systemic medical diseases that in the opinion of the investigator are likely to affect the central nervous system.

Healthy Controls:

Inclusion Criteria:

No current or past history of mental disorder as evidence by MINI or DSM-IV-TR.
No first-degree relative with an established diagnosis by a healthcare provider of a mood or psychiatric disorder.
No unstable medical disorders.

Exclusion Criteria:

Any medication for a general medical disorder that in the opinion of the investigator may affect cognitive function (e.g. corticosteroids, beta-blockers).
Consumption of alcohol within 8 hours of THINC-it tool administration.

Study design

Observational model: Case-control
Time perspective: Cross-sectional
Enrollment: 200 participants (estimated)
Patient registry: No

Groups and cohorts

Major Depressive Disorder Population
100 Individuals with DSM-5-defined MDD, aged 18-65
Other: THINC-it Tool · Other: Pencil-and-paper Cognitive Tests
Healthy Control Population
100 healthy controls matched on age, sex and years of education
Other: THINC-it Tool · Other: Pencil-and-paper Cognitive Tests

Interventions

OtherTHINC-it Tool
Digitalized cognitive test application administering the following cognitive test components: * Digit Symbol Substitution Test (DSST) * Choice Reaction Time (CRT) * One-back working memory tool * Trail Making Test B (TMT-B) * Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
OtherPencil-and-paper Cognitive Tests
Pencil-and-paper versions of the following cognitive tests: * Digit Symbol Substitution Test (DSST) * Trail Making Test B (TMT-B) * Perceived Deficits Questionnaire-5 Depression (PDQ-5-D) * Variant of Choice Reaction Time (CRT) * Variant of the One-back working memory tool

What researchers measure

Primary outcomes

Composite THINC-it Tool Score
The composite THINC-it tool score is the integrated total score of results from performance on five sub-component cognitive tests of the THINC-it tool.
Time frame: up to1 week
Digit Symbol Substitution Test (DSST) - THINC-it tool version
Time frame: Up to 1 week
Choice Reaction Time (CRT) - THINC-it tool version
Time frame: Up to 1 week
One-back working memory test - THINC-it tool version
Time frame: Up to 1 week
Trail Making Test B - THINC-it tool version
Time frame: Up to 1 week
Perceived Deficits Questionnaire 5 item for depression (PDQ-5-D) - THINC-it tool version
Time frame: Up to 1 week
Digit Symbol Substitution Test (DSST) - Pencil-and-paper version
Time frame: Up to 1 week
Choice Reaction Time (CRT) - Pencil-and-paper version
Time frame: Up to 1 week
One-back working memory test - Pencil-and-paper version
Time frame: Up to 1 week
Trail Making Test B - Pencil-and-paper version
Time frame: Up to 1 week
Perceived Deficits Questionnaire 5 item for depression (PDQ-5-D) - Pencil-and paper version
Time frame: Up to 1 week

Secondary outcomes

Endicott Workplace Productivity Scale (EWPS)
Time frame: Up to 1 week
Sheehan Disability Scale (SDS)
Time frame: Up to 1 week
Pittsburgh Sleep Quality Index (PSQI)
Time frame: Up to 1 week
Clinical Global Impression (CGI)
Time frame: Administered at one timepoint to healthy controls and to subjects with MDD after administration of primary cognitive test instruments.
Montgomery Asberg Depression Rating Scale (MADRS)
Time frame: Up to 1 week
Generalized Anxiety Disorder 7-Item (GAD-7)
Time frame: Administered at one timepoint to healthy controls and to subjects with MDD after administration of primary cognitive test instruments.
WHO-5 Well-being Index (WHO-5)
Time frame: Up to 1 week
Visual Analog Scale (VAS)
Time frame: Up to 1 week

Study locations

1 site

CRTCE/KJK Healthplex
Toronto, Ontario L5C 4E7, Canada

References and documents

Publications

Cha DS, Carmona N, Cha RH, Zhou AJ, Subramaniapillai M, Mansur RB, Lee Y, Lee JH, Lee J, Almatham F, Alageel A, Rosenblat JD, Shekotikhina M, Rong C, Harrison J, McIntyre RS. Perceived sleep quality predicts cognitive function in adults with major depressive disorder independent of depression severity. Ann Clin Psychiatry. 2019 Feb;31(1):17-26. PubMed 30372511 ↗
Cha DS, Carmona NE, Rodrigues NB, Mansur RB, Lee Y, Subramaniapillai M, Phan L, Cha RH, Pan Z, Lee JH, Lee J, Almatham F, Alageel A, Rosenblat JD, Shekotikhina M, Rong C, Harrison J, McIntyre RS. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. J Affect Disord. 2018 Oct 1;238:228-232. doi: 10.1016/j.jad.2018.05.006. Epub 2018 Jun 1. Erratum In: J Affect Disord. 2023 Nov 1;340:71. doi: 10.1016/j.jad.2023.07.062. PubMed 29886204 ↗
Carmona NE, Subramaniapillai M, Mansur RB, Cha DS, Lee Y, Fus D, McIntyre RS. Sex differences in the mediators of functional disability in Major Depressive Disorder. J Psychiatr Res. 2018 Jan;96:108-114. doi: 10.1016/j.jpsychires.2017.09.025. Epub 2017 Sep 30. PubMed 28992527 ↗
McIntyre RS, Best MW, Bowie CR, Carmona NE, Cha DS, Lee Y, Subramaniapillai M, Mansur RB, Barry H, Baune BT, Culpepper L, Fossati P, Greer TL, Harmer C, Klag E, Lam RW, Wittchen HU, Harrison J. The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction: Validation in Patients With Major Depressive Disorder. J Clin Psychiatry. 2017 Jul;78(7):873-881. doi: 10.4088/JCP.16m11329. PubMed 28858441 ↗

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Oct 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT02508493
Lead sponsor: Brain and Cognition Discovery Foundation
Collaborators: Co-Principal Investigators: Dr. Roger S. McIntyre & Dr. John Harrison, Imperial College London
Responsible party: Roger McIntyre (Executive Director, Brain and Cognition Discovery Foundation) — Principal investigator
First posted: Jul 27, 2015
Start date: Nov 2015
Primary completion: Jul 2016
Completion: Jul 2016
Last update: Oct 27, 2021

Study contacts

Roger McIntyre

principal investigator · Brain and Cognition Discovery Foundation

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Depressive Disorder→

Other studies from this sponsor

Brain and Cognition Discovery Foundation

Start the discussion